

ADA-2012 – UPDATE on SGLT2/1 inhibitors - Canagliflozin Rocks!

<https://marketpublishers.com/r/A87BE0C3C5AEN.html>

Date: June 2012

Pages: 5

Price: US\$ 140.00 (Single User License)

ID: A87BE0C3C5AEN

Abstracts

A relative assessment of new clinical data published on SGLT2 inhibitors at ADA 2012, suggests that JNJ/Mitsubishi Tanabe's canagliflozin is all set to steal the market and we foresee mega blockbuster potential. From a regulatory perspective, we see a positive risk/reward profile for Canagliflozin as unlike dapagliflozin there has been no liver enzyme elevation observed. Other notable pipeline candidates with a differentiated clinical profile include Lexicon's dual SGLT2/1 inhibitor – LX4211 - Superior post prandial glucose reduction, Boehringer Ingelheim's Empagliflozin - Solid weight reduction, Taisho Luseogliflozin - Efficacious in patients with mild to moderate renal impairment together with a decent HbA1C reduction (no hypo's observed).

Contents

COMPANIES MENTIONED

Bristole-Myers, Astrazeneca, Novo Nordisk, Astellas, Mitsubishi Tanabe, takeda,
Johnson & johnson, Lexicon

I would like to order

Product name: ADA-2012 – UPDATE on SGLT2/1 inhibitors - Canagliflozin Rocks!

Product link: <https://marketpublishers.com/r/A87BE0C3C5AEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A87BE0C3C5AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970